Navigation Links
Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
Date:4/20/2009

Abstract # 2905

DENVER, April 20 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 100th Annual Meeting 2009 that represents significant research advancements in the treatment of the most aggressive forms of invasive breast cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO)

Karmanos researchers discovered that when an FDA-approved cancer treatment typically used to treat cutaneous T-cell lymphoma was administered before a novel experimental antitumor agent -- which works best in breast cancers expressing the estrogen receptor (ER) -- estrogen receptors were reinstated in receptor-negative breast cancer cells so that treatment was also effective in fighting the difficult to treat ER-negative disease.

Research was supervised by Angelika Burger, Ph.D., director of the Translational Research Laboratory at the Karmanos Cancer Institute and professor of Pharmacology at Wayne State University in Detroit. Karri Stark, a doctoral candidate with Wayne State University's School of Medicine, presented the findings.

Researchers have paired vorinostat, known by its pharmaceutical name Zolinza(R), with Aminoflavone Prodrug (also known as AFP464) and found that AFP464 and vorinostat work together to inhibit the growth of triple-negative breast cancer cells. "Triple-negative" refers to breast cancer cells that have no estrogen, progesterone or HER2 receptors needed for currently-available, targeted anticancer therapies to work effectively.

AFP464 is now in Phase I clinical trials at the Karmanos Cancer Institute in Detroit, the Mayo Clinic in Minnesota, and other cancer research centers in Paris and Brussels in Europe.

Dr. Burger says the findings offer particular hope to those women battling triple-negative breast cancer.

"We could now find a way to treat every kind of invasive, metastatic breast cancer, the ER-positive and ER-negative types with AFP464," she said. "The synergism is very impressive. We always knew vorinostat can reprogram the expression of cancer cells."

AFP464 has been in Phase I clinical trial for the last year and a half, where doses were given to patients with solid tumors. Dr. Burger says the next step is to take the anti-cancer agent to the second phase, where researchers administer to triple-negative breast cancer patients the drug alone or in combination with vorinostat. She expects that to occur in the next year and said that Karmanos could host one of those second-phase trials.

"We are currently conducting animal experiments with the single agents and the drug combination," Dr. Burger said. "Triple-negative breast cancers might respond against that drug (AFP464)."

Triple-negative breast cancer afflicts mostly young women under the age of 40 and is more prevalent in the African-American community. About 182,460 women in the United States were diagnosed with invasive breast cancer in 2008 and about 40,480 will die from the disease, according to the American Cancer Society. Dr. Burger said that about 14 percent to 18 percent of breast cancer cases are triple-negative.

She expects that this research could translate to real-world applications in the next five years.

"These are targeted agents that are being tested," Dr. Burger said. "Having a drug available to treat triple-negative breast cancer would be a major step in fighting this disease."

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
2. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
3. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
4. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
5. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
6. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
7. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
8. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
9. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
10. Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers
11. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):